Biosimilars: A Fancy Name for Generics But Oh So Much More Disastrous

Sep 07, 2007

Over on VentureBeat, David Hamilton writes that even normally smart biotechnology investors get a little dim when talking about biosimilars and the loss of patent protection for biotech drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Director of Both, For Now

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

Behind on Testing

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

From CRISPR Lab to COVID-19 Lab

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

Nature Papers Present New CRISPR Screening Approach, Discuss CRISPR in Crop Breeding, More

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.

Menu